Lysosomal Therapeutics Inc. (LTI) discovers and develops new therapies for patients with severe neurological diseases. Our strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective platform for novel drug discovery.
http://www.lysosomaltx.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Monday
LOAD TIME
0.7 seconds
16x16
32x32
64x64
Cornelis Been
6 Dru●●●●● Road
We●●on , Massachusetts, 02493
United States
View this contact
Cornelis Been
6 Dru●●●●● Road
We●●on , Massachusetts, 02493
United States
View this contact
Cornelis Been
6 Dru●●●●● Road
We●●on , Massachusetts, 02493
United States
View this contact
BUY YOUR DOMAIN
12
YEARS
3
MONTHS
19
DAYS
GODADDY.COM, LLC
WHOIS : whois.godaddy.com
REFERRED : http://registrar.godaddy.com
PAGES IN
THIS WEBSITE
8
SSL
EXTERNAL LINKS
5
SITE IP
198.185.159.145
LOAD TIME
0.741 sec
SCORE
6.2
Lysosomal Therapeutics, Inc. (LTI) | lysosomaltx.com Reviews
https://lysosomaltx.com
Lysosomal Therapeutics Inc. (LTI) discovers and develops new therapies for patients with severe neurological diseases. Our strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective platform for novel drug discovery.
lysosomaltx.com
Management Team
https://www.lysosomaltx.com/management-team.html
Delivering cures for neurodegenerative diseases. Kees Been, Founder, President and CEO. Kees Been was formerly the President and CEO of. Pharmaceuticals, where he l. For eight years from an early-stage start-up to a respected CNS company with a broad pipeline of NCE drug compounds, its lead compound in a phase 3 program for Alzheimer’s disease and schizophrenia. He spent four years at. Daniel Geffken, CFO. Dana C. Hilt, M.D., CMO. Peter Lansbury, Ph.D., Chief Scientific Officer. Valerie Cullen, Ph.D&...
Our Science
https://www.lysosomaltx.com/our-science.html
Genetics: Linkage between Rare and Common Disease. Connection between genetic mutations in the GCase enzyme and Parkinson's. Delivering cures for neurodegenerative diseases. Lysosomal Storage: Function and Dysfuntion in Neuronal Disease. Homozygous mutations in the. Glucocerebrosidase (GCase) gene (also known as GBA1). People diagnosed with Gaucher disease have a build-up of a lipid (gloucosylceramide). Therapeutic Development in Neurodegenerative Disease.
Company Founders
https://www.lysosomaltx.com/company-founders.html
Delivering cures for neurodegenerative diseases. Dimitri Krainc, M.D., Ph.D. Scientific Founder, Chairman of the Scientific Advisory Board. Dimitri is Aaron Montgomery Ward Professor of Neurology, Chairman of the Ruth and Ken. And Brigham and Women. S Hospital. He then served on the clinical and research faculty in the Department of Neurology at MGH and Harvard Medical School. Joseph Mazzulli, Ph.D. Henri Termeer, Founder. Bob Carpenter, Founder and Chairman of the Board. Bob is a successful entrepreneur...
News
https://www.lysosomaltx.com/news.html
10142015 - Neuro Advance Boston. What's Hot in NeuroD" Panel to Feature LTI's CSO, Peter Lansbury. Genetic Engineering and Biotechnology News. Parkinsons' Disease: The Devil Is in the Protein. Lysosomal Therapeutics to use $20M to develop, test Parkinson's drug. As Promised, LTI Pulls In Big Series A to Advance Parkinson's Drug. Lysosomal Therapeutics raises $20M Series A from Sanofi, Lilly and Roche for Parkinson's drug. Lysosomal Therapeutics Receives $20M Series A for Parkinson's Disease Therapy.
Board of Directors
https://www.lysosomaltx.com/board-of-directors.html
Nessan Bermingham, Ph.D., Venture Partner at Atlas Venture. Rez Halse, Ph.D., Partner at Partners Innovation Fund. Dr Carole Nuechterlein, Head of Roche Venture Fund. Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStatin Fremont California where she was General Counsel. Clay Thorp, General Partner at Hatteras Venture Partners. Bernard Davitian has ext...
TOTAL PAGES IN THIS WEBSITE
8
Portfolio | Hatteras Venture Partners
http://hatterasvp.com/hatteras-discovery/portfolio
Technology from Johns Hopkins University’s Wilmer Eye Institute; co-founders are world renowned ophthalmology and micro particle formulation experts. Company in preclinical development with superior extended release/durable formulations for ocular diseases. Co-investors: Maryland Venture Fund. Technology from Kyoto University and Nobel-prize winning work of Shinya Yamanaka. Commercializing a personalized, regenerative medicine platform utilizing incudes pluripotent stem cells, or iPS cells. Self-assembli...
HVP IV | Hatteras Venture Partners
http://hatterasvp.com/portfolio/hvp-iv
With a strategy similar to HVP III, Hatteras Venture Partners IV (HVP IV) was launched in August 2011 with a first close of $74 million. Upon final close on January 7, 2013, HVP IV reached $125 million in investable capital. With HVP IV, Hatteras has formally launched Hatteras Discovery. An allocation of the fund focused on seed-stage companies and projects in the field of human medicine and life sciences. NuSirt Sciences, Inc. Spyryx Biosciences, Inc. With technology from Johns Hopkins University’s Wilm...
TOTAL LINKS TO THIS WEBSITE
5
Home - Lysosomal Disease Network
LDN Research Progress Report. Official List of Lysosomal Diseases. Lysosomal Diseases Educational Sites. Patient Advocacy & Support Groups. Patient & Family Meetings and Events. LDN Research Progress Report. Official List of Lysosomal Diseases. Lysosomal Diseases Educational Sites. Patient Advocacy & Support Groups. Patient & Family Meetings and Events. Lysosomal Disease Network Is. For 2018-2019 LDN Fellowship. 2018 Rare Disease Day at NIH. Event Video is Now Available. And the NIH Clinical Center.
lysosomalstorage.com
lysosomalstorage.net
lysosomalstorage.org
Lysosomal Storage Research Group
Database connection error (1): The MySQL adapter 'mysql' is not available.Database connection error (1): The MySQL adapter 'mysql' is not available.
Lysosomal Therapeutics, Inc. (LTI)
Lysosomal Therapeutics Inc. (LTI) discovers and develops new therapies for patients with severe neurological diseases affecting movement, cognition and general health. Our innovative strategy leverages the clinically-validated link between common neurodegenerative diseases and rare lysosome-based genetic disorders to establish a unique and effective platform for novel drug discovery. Gene, originally discovered in Gaucher’s disease patients. CLINICAL TRIALS and RESOURCES. OUR CANDIDATE, LTI-291. Gene is ...
Lysosomal XPERT / Page d'accueil
Error to access GNM service. Check your link please.
Internal error - {{SITENAME}}
WgShowExceptionDetails = true;. At the bottom of LocalSettings.php to show detailed debugging information. Retrieved from " http:/ Lysosome.net/index.php/Main Page. Log in / create account.
Main Page - Lysosome.org
Kafyvotlnwyqabipzyvb, Paparazzi Stalkers. IjVuhUF, Bushy Bushy. BSuKTeV, Devils sex film. RAqbiUV, Fuck my Mommy and Me. RoVpfiC, Porn cams. YtxdQbH, Free cameraboys username and passwords. Retrieved from " http:/ Lysosome.org/index.php/Main Page. Related Links [ Edit. This page was last modified on 3 August 2012, at 17:43. This page has been accessed 101,246 times. Content is available under.
Blog de lysosome - Zou, que du bonheur! - Skyrock.com
Mot de passe :. J'ai oublié mon mot de passe. Zou, que du bonheur! Mise à jour :. Abonne-toi à mon blog! On peut effectivement avoir une double personnalité. N'oublie pas que les propos injurieux, racistes, etc. sont interdits par les conditions générales d'utilisation de Skyrock et que tu peux être identifié par ton adresse internet (67.219.144.170) si quelqu'un porte plainte. Ou poster avec :. Retape dans le champ ci-dessous la suite de chiffres et de lettres qui apparaissent dans le cadre ci-contre.
lysosomes.com
The domain lysosomes.com is for sale. To purchase, call Afternic.com at 1 781-373-6847 or 855-201-2286. Click here for more details.
